m6A修饰在肝细胞癌药物治疗中作用研究进展
Research progress in m6A methylation modification in the treatment of hepatocellular carcinoma
冯加其 1刘雄青 1黄鑫昱 2刘璐 3王甘露4
作者信息
- 1. 广东医科大学第一临床医学院,广东 湛江 524023;广东医科大学深圳宝安临床医学院,广东 深圳 518101
- 2. 深圳市宝安区福永人民医院肝胆外科,广东 深圳 518101
- 3. 深圳市宝安区人民医院,广东 深圳 518101
- 4. 广东医科大学深圳宝安临床医学院,广东 深圳 518101
- 折叠
摘要
肝细胞癌(HCC)患者长期生存率不佳,药物疗效是影响其预后的重要因素.N6-甲基腺嘌呤(m6A)修饰是真核生物RNA中最丰富的修饰,可通过调节与癌症相关的生物学功能来影响癌症的发生发展及药物疗效.然而,m6A修饰在HCC药物治疗中的作用尚未完全阐明,因此,文章通过m6A修饰过程的 3 种调节成员(甲基转移酶、去甲基转移酶和结合蛋白)来论述其在HCC药物治疗中发挥的生物学作用,进而提出m6A修饰调节成员可作为HCC预后评估的生物标志物以及具有成为治疗靶点的潜力,为HCC精准医疗提供新的见解.
Abstract
The long-term survival rate of patients with hepatocellular carcinoma(HCC)is poor,and drug efficacy is an important factor affecting clinical prognosis.N6-methyladenosine(m6A)modification is the most abundant modification in eukaryotic RNA,which can affect the occurrence and development of HCC and drug efficacy by regulating cancer-related biological functions.However,the role of m6A modification in HCC drug treatment has not been fully elucidated.Therefore,the biological functions of different regulatory members of the m6A modification process(methyltransferase,demethyltransferase and binding protein)in HCC drug treatment were illustrated,proposing that regulatory members of the m6A modification process can be used as biomarkers for HCC prognosis evaluation and have the potential to become therapeutic targets and providing novel insights for HCC precision medicine.
关键词
肝细胞癌/m6A修饰/药物/系统治疗Key words
Hepatocellular carcinoma/m6A modification/Drug/Systemic treatment引用本文复制引用
基金项目
深圳市科技计划项目(JCYJ20230807144059002)
出版年
2024
国家科技期刊平台
NSTL
万方数据